Pharmaceuticals
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
2021-01-26 01:18
China Biologic Announces Extraordinary General Meeting of Shareholders
BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...
2021-01-25 21:44
511
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...
2021-01-22 12:00
588
China Jo-Jo Drugstores Hosts the First Suppliers Conference in China
HANGZHOU, China, Jan. 21, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the...
2021-01-21 21:30
5218
Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002
NANCHANG, China, Jan. 20, 2021 /PRNewswire/ -- On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were ...
2021-01-20 13:53
504
Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the Nati...
2021-01-19 19:30
3055
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy
WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ -- Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, today announced a strategic partnership to provide ...
2021-01-19 14:05
485
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies. This new collaboration combines Boeh...
2021-01-18 22:00
775
TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it ...
2021-01-18 21:00
620
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products
SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products Manuf...
2021-01-15 21:00
1864
ATIF Holdings Limited Announces Its IPO Client Soars 100% in the U.S. Trading Debut
LOS ANGELES, Jan. 13, 2021 /PRNewswire/ -- ATIF Holdings Limited (Nasdaq: ATIF, "ATIF"), a company providing business consulting and media services in Asia and North America, announces the client ofATIF, a China-based pharmaceutical and chemical products manufacturer, Qilian International Holding...
2021-01-13 21:00
8891
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval fo...
2021-01-13 21:00
666
Korea Fair Trade Commission Assigns Compliance Program Rating of "A" to Yuyu Pharma
SEOUL, South Korea, Jan. 11, 2021 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX: 000220) received Compliance Program (CP) Rating of "A" from the Korea Fair Trade Commission (FTC). Yuyu Pharma (Yuyu) established its CP team in 2016 with the help of the law firm Kim & Chang. The CP tea...
2021-01-11 22:00
3464
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...
2021-01-09 11:06
4640
Gracell Biotechnologies Announces Pricing of Initial Public Offering
SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...
2021-01-08 14:55
8374
Bioworkshops successfully passed EU QP audit
SUZHOU, China, Jan. 6, 2021 /PRNewswire/ -- In November 2020, Bioworkshops passed a European drug Qualified Person audit (QP audit) for manufacture of clinical drug substance and drug product at their Suzhou site. The ratification of compliance to EU GMP comes within a month of obtaining a Drug M...
2021-01-06 22:00
809
PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"
DAEJEON, South Korea, Jan. 4, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Wee...
2021-01-04 21:00
838
ImmVira Announces Series C Financing with Leading Specialist Investors
SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C fina...
2020-12-31 19:29
2570
Yuyu Pharma was recognized as "Family-Friendly Company" by the Ministry of Gender Equality and Family
SEOUL, South Korea, Dec. 30, 2020 /PRNewswire/ -- Yuyu Pharma(CEO Robert Wonsang Yu, KRX: 000220) received recognition from the Ministry of Gender Equality and Family for implementing family-friendly policies for their employees. This is the second-time Yuyu has received this certification from ...
2020-12-30 22:00
1203
Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients
SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...
2020-12-25 21:00
2473
Week's Top Stories
Most Reposted
AirHost Awarded by Booking.com as a Premier Partner 2021
[Picked up by 131 media titles]
2021-01-19 09:00
Nium and Cebuana Lhuillier Launch Quikz in Singapore to Expand Remittance Capabilities for Filipino Users
[Picked up by 115 media titles]
2021-01-20 10:00SAI Digital announces full-service agency expansion with Digital Marketing and Intelligent Commerce in 2021
[Picked up by 114 media titles]
2021-01-19 14:13
Score Tickets To AO21? Official Partner Of The Australian Open, TMGM Launches New Online Tennis Game With Over $20K In Prizes!
[Picked up by 110 media titles]
2021-01-21 07:16
Cornerstone Technologies Goes Public, Unveils Refreshed Brand
[Picked up by 109 media titles]
2021-01-21 11:45Most Read
PTC Appoints Mark Benjamin to Its Board of Directors
2021-01-21 22:00
10077
Wondershare Rolls out EdrawMax 10.5 with New Diagram Features and Compatibility Upgrades
2021-01-21 21:00
8642
Recon Announces Development of AI-based Control System of Electric Submersible Pump
2021-01-19 21:30
8208
Farmmi Wins Initial Round of Food Enterprise Management Awards in Lishui
2021-01-19 20:00
7438